The effect of angiotensin II receptor blocker (ARB) or thiazolidinedione (TZD) on adipocytokines and oxidative stress markers (Senri Study II)
Not Applicable
- Conditions
- Hypertensive and/or Diabetic patients
- Registration Number
- JPRN-UMIN000001456
- Lead Sponsor
- Department of Metabolic Medicine, Graduate School of Medicine, Osaka University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1)Contraindications of candesartan 2)Contraindications of Pioglitazone
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes of TBARS(Thiobarbituric acid reactive substances), highsensitive CRP, and Adiponectin at the completion of treatment form baseline
- Secondary Outcome Measures
Name Time Method Changes of waist circumference, glucose-lipid metabolic parameters, and blood pressure
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link ARBs or TZDs to adipocytokine regulation in hypertensive/diabetic patients?
How do ARBs and TZDs compare in reducing oxidative stress markers in metabolic syndrome patients?
Which biomarkers predict differential response to ARB or TZD therapy in type 2 diabetes and hypertension?
What adverse events are associated with long-term ARB or TZD use in cardiovascular/metabolic disease patients?
How do ARB and TZD mechanisms synergize with SGLT2 inhibitors in diabetes/hypertension treatment?